Summary
Hydrocodone bitartrate (HB) and acetaminophen (APAP) combination products are known to be abused via oral, intranasal, and intravenous self-administration. Benzhydrocodone HCl (KP201) is a prodrug of hydrocodone with limited bioavailability when taken intranasally or intravenously, or taken orally at supratherapeutic doses. This study assessed the abuse liability, relative bioavailability, and safety of KP201/APAP, compared with that of HB/APAP (Norco®), when administered at supratherapeutic oral doses to non-dependent, recreational opioid users. Both KP201/APAP and HB/APAP were generally well tolerated and had similar Drug Liking scores, but KP201/APAP displayed lower peak and cumulative systemic exposure to hydrocodone at high and mid oral doses.
Register to download
Oral Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone
You may also be interested in:
Video
Lenexa Kansas - Clinical Pharmacology Center
PRA Health Sciences offer a full-suite of global, clinical pharmacology services. Our Lenexa, Kansas, clinic is co-located with our bioanalytical…
Poster
Pharmacokinetic Characteristics of Intranasal Administration of Oxycodone ARIR
Abuse of prescription opioids continues to be a serious public health concern, with as many as 12.5 million individuals aged 12 or older reporting…
Capability
ECG Assessments in Renal and Hepatic Impaired Patients
PRA’s dedicated early phase professionals leverage proven expertise in renal and hepatic impairment to provide clients with high quality ECG…